Bitaraf Mohammad Ali, Alikhani Mazdak, Tahsili-Fahadan Pouya, Motiei-Langroudi Rouzbeh, Zahiri Alireza, Allahverdi Mahmoud, Salmanian Soraya
Department of Neurosurgery, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
J Neurosurg. 2006 Dec;105 Suppl:168-74. doi: 10.3171/sup.2006.105.7.168.
Glomus jugulare tumors (GJT) have traditionally been treated by surgery or fractionated external-beam radiotherapy. The aim of this retrospective study was to determine the tumor control rate, clinical outcome, and short-term complications of stereotactic radiosurgery in subsets of patients who are poor candidates for these procedures, based on age, medical problems, tumor size, or prior treatment failure.
The Leksell Gamma Knife was used to treat 16 patients harboring symptomatic, residual, recurrent, or unresectable GJTs. The age of the patients ranged from 12 to 77 years (median 46.5 years). Gamma Knife surgery (GKS) was performed as primary treatment in five patients (31.3%). Microsurgery preceded radiosurgery in 10 patients (62.5%) and fractionated radiotherapy in three patients (18.8%). The median tumor volume was 9.8 cm3 (range 1.7-20.6 cm3). The median marginal dose applied to a mean isodose volume of 50% (range 37-70%) was 18 Gy (range 14-20 Gy). Neurological follow-up examinations revealed improved clinical status in 10 patients (62.5%), a stable neurological status in six (37.5%), and no complications. After radiosurgery, follow-up imaging was conducted in 14 patients; the median interval from GKS to the last follow up was 18.5 months (range 4-28 months). Tumor size had decreased in six patients (42.9%), and the volume remained unchanged in the remaining eight (57.1%). None of the tumors increased in volume during the observation period.
According to the authors' experience, GKS represents a useful therapeutic option to control symptoms and may be safely conducted in patients with primary or recurrent GJTs with no death and no acute morbidity. Because of the tumor's naturally slow growth rate, however, long-term follow-up data are needed to establish a cure rate after radiosurgery.
传统上,颈静脉球瘤(GJT)通过手术或分次外照射放疗进行治疗。本回顾性研究的目的是确定立体定向放射外科治疗在因年龄、内科问题、肿瘤大小或既往治疗失败而不适合这些治疗的患者亚组中的肿瘤控制率、临床结局和短期并发症。
使用Leksell伽玛刀治疗16例有症状、残留、复发或不可切除的颈静脉球瘤患者。患者年龄范围为12至77岁(中位年龄46.5岁)。5例患者(31.3%)接受伽玛刀手术(GKS)作为初始治疗。10例患者(62.5%)在放射外科治疗前接受了显微手术,3例患者(18.8%)在放射外科治疗前接受了分次放疗。中位肿瘤体积为9.8 cm³(范围1.7 - 20.6 cm³)。应用于平均等剂量体积50%(范围37 - 70%)的中位边缘剂量为18 Gy(范围14 - 20 Gy)。神经学随访检查显示,10例患者(62.5%)临床状况改善,6例患者(37.5%)神经学状况稳定,且无并发症。放射外科治疗后,14例患者进行了随访影像学检查;从伽玛刀手术到最后一次随访的中位间隔时间为18.5个月(范围4 - 28个月)。6例患者(42.9%)肿瘤大小减小,其余8例患者(57.1%)肿瘤体积保持不变。在观察期内,无一例肿瘤体积增大。
根据作者的经验,伽玛刀手术是控制症状的一种有效治疗选择,对于原发性或复发性颈静脉球瘤患者可安全进行,且无死亡和急性并发症。然而,由于肿瘤自然生长缓慢,需要长期随访数据来确定放射外科治疗后的治愈率。